Fresenius Medical Care Reports Strong Financial Performance and Strategic Progress
Fresenius Medical Care (FME) reported strong financial performance in its fiscal year ending May 2026, with organic revenue growth of 8% driven by all operating segments. The company successfully completed a EUR 1 billion share buyback program and announced the launch of its FME Reignite strategy to drive future value creation.
Topics: dividend profitability improvement share buyback strategic plan